Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma

Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma

PR Newswire

SAN MATEO, Calif., Aug. 26, 2026

Craig Gibbs, PhD, MBA, appointed President and Chief Executive OfficerEllen Lubman, MBA, joins as Chief Business and Strategy OfficerOncology veteran Tim Clackson, PhD, appointed to the Board of Directors FDA grants Safe to Proceed for the Pivotal Phase 3 sTEADfast Clinical Study SAN MATEO, Calif., Aug. 26, 2026 /PRNewswire/ -- Vivace Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class cancer therapies that target the Hippo signaling pathway, today announced a series of leadership appointments that position the company for its next phase of growth as it prepares to advance its lead candidate, VT3989, into the pivotal Phase 3 sTEADfast registrational trial in mesothelioma patients previously treated with both combination immunotherapy and combination chemotherapy. Craig Gibbs, Ph.D. has been appointed President and Chief Executive Officer, Ellen Lubman has joined as Chief Business and Strategy Officer, and industry veteran Tim Clackson, Ph.D., has been appointed to the company's Board of Directors.